Pemeriksaan Tunggal Kadar Osteopontin Serum dan CA 125 untuk Prediktor Keganasan Tumor Ovarium Tipe Epitel: Inferior dibandingkan dengan Pemeriksaan Gabungan

Aditiyono Aditiyono; Ali Budi Harsono; Gatot N.A. Winarno; Supriadi Gandamihardja; Ardhanu Kusumanto; Herman Susanto

doi:10.24198/obgynia.v1n1.55

Pemeriksaan Tunggal Kadar Osteopontin Serum dan CA 125 untuk Prediktor Keganasan Tumor Ovarium Tipe Epitel: Inferior dibandingkan dengan Pemeriksaan Gabungan

Aditiyono Aditiyono,^(1*) Ali Budi Harsono,⁽²⁾ Gatot N.A. Winarno,⁽³⁾ Supriadi Gandamihardja,⁽⁴⁾ Ardhanu Kusumanto,⁽⁵⁾ Herman Susanto,⁽⁶⁾

(1)
(2) Departmen Obstetri dan Ginekologi Fakultas Kedokteran Universitas Padjadjaran/RSUP Dr. Hasan Sadikin Bandung
(3) Departmen Obstetri dan Ginekologi Fakultas Kedokteran Universitas Padjadjaran/RSUP Dr. Hasan Sadikin Bandung
(4) Departmen Obstetri dan Ginekologi Fakultas Kedokteran Universitas Padjadjaran/RSUP Dr. Hasan Sadikin Bandung
(5) Fakultas Kedokteran Universitas Gajah Mada/RS Sardjito Yogyakarta
(6) Departmen Obstetri dan Ginekologi Fakultas Kedokteran Universitas Padjadjaran/RSUP Dr. Hasan Sadikin Bandung
(*) Corresponding Author

Abstract

Abstrak
Tujuan: Membandingkan penanda tumor osteopontin (OPN), cancer antigen 125 (CA125), kombinasi sebagai prediktor keganasan pada penderita tumor ovarium.
Metode: Penelitian cross sectional ini dilakukan pada pasien dengan keganasan pada kista ovarium jenis epitel. Analisis data dilakukan secara univariat dan bivariat.
Hasil: 47 pasien dengan hasil hitopatologi jinak dan 43 dengan hasil histopatologi ganas masuk dalam penelitian. Hasil nilai median CA125 kelompok ganas dibanding kelompok jinak (142,2 vs 61,030, p < 0,05), cut off point CA125 99,9 U/mL, sensitivitas 76,7% dan spesifisitas 61,7%.
Diskusi: Kombinasi CA125 dan OPN memiliki sensitivitas lebih rendah dibandingkan CA125. Kombinasi CA125 dan OPN akan meningkatkan spesifitas, nilai duga positif dan akurasi yang lebih baik. Tumor marker OPN tidak tepat digunakan untuk proses deteksi dini, tetapi lebih tepat untuk penegakan diagnosis lebih baik dibandingkan dengan gold standard CA125.
Kesimpulan: Kombinasi OPN dan CA125 memiliki nilai tingkat akurasi paling tinggi apabila dibandingkan pemeriksaan tunggal CA125, OPN.

Single Check of Serum Ostepontin and CA 125 Levels as A Predictor of Malignancy in Epitheliaal Ovarium Tumor is Inferior to Combined Examination

Abstract
Objective: To compare the sensitivity, specificity, expected value positive, expected value negative and accuracy among osteopontin (OPN), cancer antigen 125 (CA125), and combination as predictor of malignancy in ovarian tumor patients.
Method: A cross sectional study was done to compare parameters OPN and CA125 in determining malignancy of ovarian cysts. Data analysis was performed by univariate and bivariate analysis. Results: A total of 47 subjects were included with benign histopathological result and 43 subjects with malignant histopathological result. The median value of CA125 in malignant group was compared to that of benign group (142.2 vs. 61.030, p value <0.05), the cut-off point of CA125 was 99.9 U/mL with sensitivity of 76.7% and specificity of 61.7%.
Discussion: Combination of CA125 dan OPN has lower sensitivity compared to single tumor marker CA125. This combination will increase specificity, positive predictive value and accuracy. The OPN is inappropriate when used for early detection instead is suggested for diagnostic value risk predictor for malignancy in ovarian tumor compared to gold standard CA125.
Conclusion: Combination OPN dan CA125 has higher accuracy compared to single CA125, and OPN. OPN was useful biomarker for predicting ovarian malignancy.

Key words: Epithelial ovarian tumor, OPN, CA 125, predictor for ovarian malignancy

Keywords

tumor ovarium tipe epitel, OPN, CA 125, prediktor keganasan

Full Text:

PDF

References

World Health Organization. GLOBOCAN 2012: estimated cancer incidence, mortality and pravalence wordwide in 2012. 2012 [updated 2012; Diunduh 1 Januari 2016]; Tersedia dari: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.

Bast RC, Jr. Biomarkers for ovarian cancer: new technologies and targets to address persistently unmet needs. Cancer biomarkers : section A of Disease markers. 2010;8(4-5):161-6.

Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. J Clin Pathol. 2005;58(3):308-12.

Nakae M, Iwamoto I, Fujino T, Maehata Y, Togami S, Yoshinaga M, et al. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. The journal of obstetrics and gynaecology research. 2006;32(3):309-14.

Sarojini S, Tamir A, Lim H, Li S, Zhang S, Goy A, et al. Early detection biomarkers for ovarian cancer. J Oncol. 2012;2012:709049.

Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Molecular & cellular proteomics : MCP. 2004;3(4):355-66.

Cohen JG, White M, Cruz A, Farias-Eisner R. In 2014, can we do better than CA125 in the early detection of ovarian cancer? World Journal of Biological Chemistry. 2014;5(3):286-300.

Shevde LA, Samant RS. Role of osteopontin in the pathophysiology of cancer. Matrix Biol. 2014;37:131-41.

Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004;90(10):1877-81.

Wang YD, Chen H, Liu HQ, Hao M. Correlation between ovarian neoplasm and serum levels of osteopontin: a meta-analysis. Tumour Biol. 2014;35(12):11799-808.

Lan Z, Fu D, Yu X, Xi M. Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis. Familial Cancer. 2016;15(2):221-30.

Field A. Discovering statistics using IBM SPSS statistics.Edisi ke ke-4. London: Sage; 2013.

Howlader N, Noone A, Krapcho M, Garshell J, Neyman N, Altekruse S, et al. SEER Cancer Statistics Review, 1975-2011. National Cancer Institute Bethesda, MD. 2014(posted to the SEER web site, April 2014).

Cannistra SA. Cancer of the ovary. The New England journal of medicine. 2004;351(24):2519-29.

Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014;64(1):9-29.

Erondu CO, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy M, Cote ML, et al. The Association Between Body Mass Index and Presenting Symptoms in African American Women with Ovarian Cancer. Journal of Women's Health. 2016;25(6):571-8.

Rein BJ, Gupta S, Dada R, Safi J, Michener C, Agarwal A. Potential markers for detection and monitoring of ovarian cancer. J Oncol. 2011;2011:475983.

Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, et al. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer prevention research. 2011;4(9):1401-8.

Li J, Dowdy S, Tipton T, Podratz K, Lu WG, Xie X, et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert review of molecular diagnostics. 2009;9(6):555-66.

McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecologic oncology. 2004;95(1):9-15.

Bao LH, Sakaguchi H, Fujimoto J, Tamaya T. Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers. Journal of Biomedical Science. 2007;14(3):373-81.

Hu ZD, Wei TT, Yang M, Ma N, Tang QQ, Qin BD, et al. Diagnostic value of osteopontin in ovarian cancer: a meta-analysis and systematic review. PLoS One. 2015;10(5):e0126444.

DOI: http://dx.doi.org/10.24198/obgynia.v1n1.55